RCMI Coordinating Center (RCMI CC) Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Ochieng, Josiah
PropertyValue
overview My laboratory has investigated the potential role of fetuin-A (also known as alpha 2HS glycoprotein) in tumor progression for the past 20 years. In 2013, we demonstrated and reported that fetuin-A drives the progression of head and neck squamous cell carcinomas. More recently a number of studies have indicated that fetuin-A is up-regulated in a number of solid tumors including pancreatic, breast and prostate tumors. We have now demonstrated (published data) that fetuin-A is a major driver of growth and metastasis in glioblastomas. We will soon embark on pre-clinical studies using mouse models for glioblastomas. This study is of immense interest to us and we would like to engage as many collaborators as possible. Currently our focus is to determine the mechanisms by which fetuin-A modifies adhesion and growth competent exosomes during tumor growth and metastasis. I am also interested in looking at the role of fetuin-A in prostate cancer progression. This disease disproportionately affects men of African descent.
One or more keywords matched the following items that are connected to Ochieng, Josiah
Item TypeName
Grant INTERACTIONS OF GELATINASES WITH SERUM/MEMBRANE PROTEIN
Grant Role of Fetuin-A in Tumor Cell Growth
Academic Article Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes.
Academic Article Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer.
Academic Article Fetuin-A ({alpha}2HS-glycoprotein) is a major serum adhesive protein that mediates growth signaling in breast tumor cells.
Academic Article Fetuin-A triggers the secretion of a novel set of exosomes in detached tumor cells that mediate their adhesion and spreading.
Academic Article Fetuin-A (a2HS-glycoprotein) is a serum chemo-attractant that also promotes invasion of tumor cells through Matrigel.
Academic Article Alpha-2 Heremans Schmid Glycoprotein (AHSG) modulates signaling pathways in head and neck squamous cell carcinoma cell line SQ20B.
Academic Article Fetuin-A associates with histones intracellularly and shuttles them to exosomes to promote focal adhesion assembly resulting in rapid adhesion and spreading in breast carcinoma cells.
Academic Article Fetuin-A (alpha 2HS glycoprotein) modulates growth, motility, invasion, and senescence in high-grade astrocytomas.
Academic Article Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes.
Academic Article Extracellular histones are the ligands for the uptake of exosomes and hydroxyapatite-nanoparticles by tumor cells via syndecan-4.
Academic Article Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities.
Academic Article Alpha 2-HS glycoprotein (fetuin-A) modulates murine skin tumorigenesis.
Academic Article Interactions of alpha2-HS-glycoprotein (fetuin) with MMP-3 and murine squamous cell carcinoma cells.
Academic Article The serum glycoprotein fetuin-A promotes Lewis lung carcinoma tumorigenesis via adhesive-dependent and adhesive-independent mechanisms.
Concept Variant Surface Glycoproteins, Trypanosoma
Academic Article Novel mechanism that Trypanosoma cruzi uses to adhere to the extracellular matrix mediated by human galectin-3.
Academic Article The interactions of alpha 2HS glycoprotein with metalloproteinases.
Academic Article The rapid endocytic uptake of fetuin-A by adherent tumor cells is mediated by Toll-like receptor 4 (TLR4).
Academic Article Fetuin-A Promotes 3-Dimensional Growth in LNCaP Prostate Cancer Cells by Sequestering Extracellular Vesicles to Their Surfaces to Act as Signaling Platforms.
Search Criteria
  • Glycoproteins
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support